Broadcast Date: April 2, 2019
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Biologic drugs have dominated the biopharmaceutical market in recent years and show no signs of slowing. While there is no shortage of therapeutic targets for drug developers designing monoclonal antibodies (mAB), validating those targets for clinical efficacy in various disease models is growing increasingly difficult. Since IL-11 was recently identified as an essential cytokine for inflammation and fibrosis, Enleofen and Aldevron developed monoclonal anti-IL-11 and anti-IL11RA antibodies for the treatment of non-alcoholic steatohepatitis (NASH) and other conditions. Lead clones of each class are highly potent inhibitors of IL-11 signaling and block the transformation of fibroblasts or hepatic stellate cells into myofibroblasts. Across several preclinical models of fibrotic diseases, including but not limited to NASH, antibody treatment prevents and reverses fibrosis, preserves organ function and is anti-inflammatory. Response to treatment can be monitored using a variety of biomarkers (exemplified by alanine aminotransferase in NASH), facilitating patient stratification, dose selection and early demonstration for proof of mechanism in clinical trials. Taken together, preclinical studies show that targeting IL-11 using monoclonal antibodies holds excellent promise for the treatment of organ dysfunction, fibrosis, and inflammation in liver disease and beyond.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
Stuart Cook, PhD
Imperial College London
Sebastian Schäfer, PhD
Assisting with the Q&A session: